Selective insulin receptor modulators (SIRM): a new class of antidiabetes drugs?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells.The Indian journal of medical research · 2018
   Article
2. Insulin Receptor Isoforms in Physiology and Disease: An Updated View.Endocrine reviews · 2017
   Review
3. The Role of Insulin Receptor Isoforms in Diabetes and Its Metabolic and Vascular Complications.Journal of diabetes research · 2017
   Review
4. Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation.Nucleic acids research · 2015
   Article
5. Potentiation of insulin-mediated glucose lowering without elevated hypoglycemia risk by a small molecule insulin receptor modulator.PloS one · 2015
   Article
6. Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders.Journal of diabetes science and technology · 2014
   Article
7. Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity.PloS one · 2014
   Article
8. Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia.mAbs
   Article

Corrections and comments

• Comment on
  A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control.2012

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as